Key points from article :
Illumina will put down a total of $8 billion to reacquire its former spinout Grail.
Both companies expect it all to come together in 2021.
Grail has on its calendar two commercial launches of tumor-screening tests.
Currently owns 14.5% of Grail, and its full takeover promises to plunge deeper into the clinical testing markets.
Two companies aim for a full FDA submission and approval starting in 2023.
“We are thrilled to welcome Grail back to Illumina to help transform cancer care using genomics and our [next-generation sequencing] platform," - Illumina President and CEO Francis deSouza.
Future projects include blood-based tests for monitoring the effectiveness of treatments at eliminating residual disease.
“Multi-cancer early detection technology could address a tremendous unmet need and reduce cancer burden worldwide," - Grail CEO Hans Bishop.
Illumina will continue to act as a sequencing partner for diagnostic test makers.
